Depemokimab: A twice yearly anti-IL 5 biologic for chronic rhinosinusitis with nasal polyps (CRSwNP) - A narrative review.
Depemokimab showed a statistically significant reduction in nasal polyp score and nasal obstruction in severe CRSwNP patients at 52 weeks, but the clinical significance of these changes needs further evaluation.
Where it sits
this study against the rest of the eloralintide corpusSummary and findings
This narrative review discusses depemokimab, a monoclonal antibody targeting interleukin-5, focusing on its pharmacokinetics, pharmacodynamics, and clinical efficacy in chronic rhinosinusitis with nasal polyps (CRSwNP). In Phase 3 trials involving 528 severe adult CRSwNP patients, depemokimab showed a reduction in total endoscopic nasal polyp score and nasal obstruction. No therapeutic claims are made.
Abstract
Depemokimab is a monoclonal antibody that targets interleukin-5 with enhanced binding affinity and an extended terminal elimination half‑life of 6-8 weeks. The unique pharmacodynamic features of depemokimab enable sustained suppression of type 2 inflammation with twice‑yearly subcutaneous dosing. This narrative review provides details of depemokimab's molecular profile, pharmacokinetics, and pharmacodynamics and results regarding the clinical efficacy and safety of depemokimab from recently published Phase 3 clinical trials for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). In 528 severe adult CRSwNP patients (ANCHOR‑1/‑2 trials), depemokimab achieved Δ total endoscopic nasal polyp score by -0.70 (<i>p</i> < .001) and Δ nasal obstruction verbal response scale by -0.24 (<i>p</i> = .003) at week 52, compared to placebo. Twice‑yearly 100 mg depemokimab provides durable eosinophil suppression and with a safety profile comparable to placebo in Phase 3 trials for CRSwNP. Future work should refine biomarkers and assess comparative cost‑effectiveness and long‑term adherence, safety, and effectiveness.
Background
This paper addresses the role of depemokimab in treating chronic rhinosinusitis with nasal polyps (CRSwNP), a condition characterized by type 2 inflammation. Prior studies have established the involvement of interleukin-5 in eosinophilic inflammation, making it a target for biologic therapies. This review is significant as it compiles findings from Phase 3 trials to evaluate the clinical efficacy and safety of depemokimab.
Methods
The review summarizes findings from Phase 3 clinical trials (ANCHOR-1/2) involving 528 severe adult CRSwNP patients. The primary outcome measures included changes in total endoscopic nasal polyp score and nasal obstruction verbal response scale. The dosing regimen was twice-yearly subcutaneous administration of 100 mg.
Results
The primary endpoint showed a Δ total endoscopic nasal polyp score by -0.70 (p<0.001) at week 52. Additionally, a Δ nasal obstruction verbal response scale by -0.24 (p=0.003) was observed at the same time point. These findings suggest a statistically significant reduction in both measures compared to placebo.
Interpretation
While the results indicate statistically significant improvements, the clinical significance of a -0.70 change in nasal polyp score and -0.24 in nasal obstruction may require further evaluation to determine practical implications for patients. The study's reliance on previously published trials and lack of long-term data limit the conclusions that can be drawn. Additionally, the findings should be interpreted cautiously due to potential confounding factors not addressed in the review.
Key findings
- Δ total endoscopic nasal polyp score by -0.70, p<0.001, at week 52, n=528.
- Δ nasal obstruction verbal response scale by -0.24, p=0.003, at week 52, n=528.
- Terminal elimination half-life of 6-8 weeks.
- Dosing frequency: twice-yearly 100 mg subcutaneously.
Limitations
- Not a primary research study; narrative review format.
- Relies on previously published Phase 3 trial data.
- No long-term follow-up data reported.
- Potential confounding factors not addressed.